GlassScriptPhysician profile
Sahar Eftekhar
NPI 1376819565
$15,130.40
in general payments reported to CMS, 2019-2025
33 companies · $1,946 in 2025
The $1,946 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,215 · 2020: $2,076 · 2021: $2,526 · 2022: $2,636 · 2023: $1,896 · 2024: $1,837 · 2025: $1,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,629 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,628.81 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $2,102.86 | 2019-2025 | Trintellix |
| Abbvie INC. | $2,028.02 | 2022-2025 | Vraylar |
| Sunovion Pharmaceuticals INC. | $1,809.12 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $1,737.66 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,575.78 | 2020-2025 | Caplyta |
| Allergan, INC. | $1,034.41 | 2019-2020 | |
| Lundbeck LLC | $969.27 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $769.16 | 2019-2025 | Spravato |
| Bausch Health US, LLC | $502.40 | 2019-2025 | Aplenzin, Wellbutrin |
| Neos Therapeutics, LP | $418.77 | 2019-2024 | Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $413.34 | 2020-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $285.30 | 2019-2023 | Austedo Xr |
| Supernus Pharmaceuticals, INC. | $203.95 | 2022-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $181.11 | 2019-2024 | Jornay Pm |
| Neurocrine Biosciences, INC. | $149.79 | 2021-2025 | Ingrezza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $120.17 | 2024-2025 | Cobenfy |
| Shire North American Group INC | $111.21 | 2019 | |
| Axsome Therapeutics, INC. | $99.86 | 2023-2025 | Auvelity |
| Alkermes, INC. | $85.37 | 2023 | Lybalvi |
| Adlon Therapeutics L.P. | $69.30 | 2019-2021 | |
| Corium, LLC | $68.35 | 2022-2025 | Azstarys |
| Almatica Pharma LLC | $58.34 | 2021-2022 | |
| Tris Pharma INC | $47.49 | 2023 | Dyanavel Xr |
| Biogen, INC. | $46.68 | 2025 | Zurzuvae |
| Alfasigma USA, INC. | $44.90 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $36.44 | 2025 | Jornay Pm |
| Eisai INC. | $32.62 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $30.98 | 2019 | |
| Tms Neurohealth Centers INC. | $29.08 | 2025 | Tms Neurohealth Centers INC. |
| Noven Therapeutics, LLC | $18.44 | 2023 | Secuado |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.28 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $18.14 | 2021 | |
| Owp Pharmaceuticals, INC. | $13.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sahar Eftekhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.